“Novo Nordisk’s uphill battle in the counterfeit weight loss craze”

Tom Moga was quoted in the Life Sciences Intellectual Property Review (LSIPR) article, "Novo Nordisk’s uphill battle in the counterfeit weight loss craze," which discusses Novo Nordisk's efforts to combat counterfeit weight-loss drugs. In the article, Moga highlights the increasing sophistication of counterfeiters and the international challenges involved. He also emphasized the complexity and critical nature of safeguarding patient safety in the growing market for products like Ozempic.